OBJECTIVE: To report a case of torsade de pointes in a patient receiving moxifloxacin. CASE SUMMARY: An 87-year-old woman was admitted to the hospital for pneumonia, and antibiotic therapy with intravenous moxifloxacin 400 mg/day was initiated. The patient was noted to have significant QTc interval prolongation 2 hours after administration of moxifloxacin and developed torsade de pointes 8-10 hours after moxifloxacin administration. She was converted back to normal sinus rhythm after a precordial thump. Moxifloxacin was discontinued, and the woman's QTc interval subsequently returned to baseline. DISCUSSION: Torsade de pointes is a life-threatening arrhythmia that has previously been associated with the use of fluoroquinolones. Minimal information is available regarding the risk of torsade de pointes with moxifloxacin. According to the Naranjo probability scale, the episode in this case was probably related to administration of intravenous moxifloxacin. CONCLUSIONS: In patients with underlying risk factors for a prolonged QT interval, the use of moxifloxacin can lengthen the interval further and ultimately trigger episodes of torsade de pointes. Moxifloxacin administration in these patients therefore should be administered and monitored judiciously.
OBJECTIVE: To report a case of torsade de pointes in a patient receiving moxifloxacin. CASE SUMMARY: An 87-year-old woman was admitted to the hospital for pneumonia, and antibiotic therapy with intravenous moxifloxacin 400 mg/day was initiated. The patient was noted to have significant QTc interval prolongation 2 hours after administration of moxifloxacin and developed torsade de pointes 8-10 hours after moxifloxacin administration. She was converted back to normal sinus rhythm after a precordial thump. Moxifloxacin was discontinued, and the woman's QTc interval subsequently returned to baseline. DISCUSSION: Torsade de pointes is a life-threatening arrhythmia that has previously been associated with the use of fluoroquinolones. Minimal information is available regarding the risk of torsade de pointes with moxifloxacin. According to the Naranjo probability scale, the episode in this case was probably related to administration of intravenous moxifloxacin. CONCLUSIONS: In patients with underlying risk factors for a prolonged QT interval, the use of moxifloxacin can lengthen the interval further and ultimately trigger episodes of torsade de pointes. Moxifloxacin administration in these patients therefore should be administered and monitored judiciously.
Authors: Diana M Cave; Raul J Gazmuri; Charles W Otto; Vinay M Nadkarni; Adam Cheng; Steven C Brooks; Mohamud Daya; Robert M Sutton; Richard Branson; Mary Fran Hazinski Journal: Circulation Date: 2010-11-02 Impact factor: 29.690
Authors: Joffrey Ducroq; H Moha ou Maati; S Guilbot; S Dilly; E Laemmel; C Pons-Himbert; J F Faivre; P Bois; O Stücker; M Le Grand Journal: Br J Pharmacol Date: 2009-08-24 Impact factor: 8.739
Authors: Tao Yang; Young Wook Chun; Dina M Stroud; Jonathan D Mosley; Bjorn C Knollmann; Charles Hong; Dan M Roden Journal: Circulation Date: 2014-06-03 Impact factor: 29.690
Authors: Pei-Chi Yang; Kevin R DeMarco; Parya Aghasafari; Mao-Tsuen Jeng; John R D Dawson; Slava Bekker; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Igor Vorobyov; Colleen E Clancy Journal: Circ Res Date: 2020-02-24 Impact factor: 17.367